Neurocrine Biosciences Files 8-K on Financial Results
Ticker: NBIX · Form: 8-K · Filed: 2024-02-07T00:00:00.000Z
Sentiment: neutral
Topics: earnings, financial-results, 8-K, corporate-update
TL;DR
**NBIX just dropped an 8-K on financial results, get ready for earnings details.**
AI Summary
Neurocrine Biosciences, Inc. filed an 8-K on February 7, 2024, to report its results of operations and financial condition. This filing, under Items 2.02 and 9.01, indicates that the company is providing an update on its financial performance, likely including earnings or other key financial metrics. For investors, this matters because it offers a timely glimpse into the company's financial health and operational efficiency, which can influence stock price and future investment decisions.
Why It Matters
This filing provides investors with crucial, up-to-date financial information, enabling them to assess Neurocrine Biosciences' performance and make informed decisions about their investment.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial results, which is standard for public companies and does not inherently signal high risk.
Analyst Insight
A smart investor would review the full financial statements and exhibits once they are available to understand the specifics of Neurocrine Biosciences' performance and how it aligns with their investment thesis.
Key Players & Entities
- Neurocrine Biosciences, Inc. (company) — registrant filing the 8-K
- February 7, 2024 (date) — date of earliest event reported and filing date
- 0-22705 (string) — Commission File Number
- 33-0525145 (string) — IRS Employer Identification No.
- 12780 El Camino Real, San Diego, CA 92130 (string) — principal executive offices address
- (858) 617-7600 (string) — registrant's telephone number
- NBIX (string) — trading symbol for Common Stock
- Nasdaq Global Select Market (string) — exchange where Common Stock is registered
FAQ
What is the purpose of this 8-K filing by Neurocrine Biosciences, Inc.?
Neurocrine Biosciences, Inc. filed this 8-K to report on its 'Results of Operations and Financial Condition' under Item 2.02 and 'Financial Statements and Exhibits' under Item 9.01, as indicated in the 'ITEM INFORMATION' section of the filing.
When was the earliest event reported in this 8-K filing?
The 'Date of Report (Date of earliest event reported)' for this 8-K filing was February 7, 2024.
What is the trading symbol and the exchange where Neurocrine Biosciences, Inc.'s common stock is registered?
The trading symbol for Neurocrine Biosciences, Inc.'s Common Stock, $0.001 par value, is NBIX, and it is registered on the Nasdaq Global Select Market, as stated under 'Securities registered pursuant to Section 12(b) of the Act'.
Is Neurocrine Biosciences, Inc. considered an emerging growth company?
No, Neurocrine Biosciences, Inc. is not an emerging growth company, as indicated by the unchecked box next to 'Emerging growth company' in the filing.
What is the business address and phone number of Neurocrine Biosciences, Inc.?
The business address for Neurocrine Biosciences, Inc. is 12780 El Camino Real, San Diego, CA 92130, and their telephone number is (858) 617-7600, as listed in the 'BUSINESS ADDRESS' section.
Filing Stats: 508 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-02-07 07:00:53
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value NBIX Nasdaq Global Select Mar
Filing Documents
- nbix-20240207.htm (8-K) — 23KB
- q4-2023xearningsrelease.htm (EX-99.1) — 225KB
- nbix-20240207_g1.jpg (GRAPHIC) — 18KB
- 0000914475-24-000033.txt ( ) — 437KB
- nbix-20240207.xsd (EX-101.SCH) — 2KB
- nbix-20240207_lab.xml (EX-101.LAB) — 23KB
- nbix-20240207_pre.xml (EX-101.PRE) — 12KB
- nbix-20240207_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On February 7, 2024, Neurocrine Biosciences, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit Description 99.1 Press Release dated February 7, 2024 104 Cover Page Interactive Data File
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROCRINE BIOSCIENCES, INC. Dated: February 7, 2024 /s/ Matthew C. Abernethy Matthew C. Abernethy Chief Financial Officer (Duly authorized officer and Principle Financial Officer)